Newsroom

Articles
SMS AFYA-YETU

Interview with Natalie Roberts : COVID-19 Alert and SMS Afia Yetu projects

Natalie Roberts is the director of studies at Crash and program manager at the MSF Foundation. During the first wave of the COVID-19 pandemic, she was involved in the implementation of two digital health applications.

Here she discusses the field of digital health and the challenge that COVID represented in the research on these issues. In this interview, we discover the needs behind the "Alerte-Niger" and "SMS Afia Yetu" projects, the stages of their development, but also the obstacles encountered by the MSF teams (the health context, relations with partners, preconceived ideas about the population).

Read more

Headline

MSF Foundation in Video

  • Officially launching of Antibiogo : Webinar
    Vidéos

    Officially launching of Antibiogo : Webinar

  • AdreUne
    Vidéos

    Report from Adre in Chad, where MSF Foundation teams explore the needs for pediatric rehabilitation.

  • YemenUne_en
    Vidéos

    Reportage in Haydan, Yemen, on the development of the rehabilitation care in the MSF sites.

More articles

News

  • Articles
    Antibiogo

    Antibiogo: facts and impacts in the fight against antimicrobial resistance

    The World Health Organization's Global AMR Awareness Week is a worldwide campaign to raise awareness and understanding of the problem of antimicrobial resistance. To mark the occasion, here is a series of infographics to help you better understand the hope that Antibiogo, a new diagnostic tool holds for combating this threat on public health.

    Read more
More articles

Publications

  • Publications
    Étude Fièvre Jaune

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
  • Publications
    Étude Fièvre Jaune

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
More articles

Press Review

More articles
No news for now.